The estimated Net Worth of Paul Berg is at least $3.82 million dollars as of 30 April 2007. Paul Berg owns over 7,500 units of Gilead Sciences stock worth over $1,031,985 and over the last 21 years Paul sold GILD stock worth over $2,792,740.
Paul has made over 23 trades of the Gilead Sciences stock since 2003, according to the Form 4 filled with the SEC. Most recently Paul exercised 7,500 units of GILD stock worth $40,575 on 30 April 2007.
The largest trade Paul's ever made was exercising 20,000 units of Gilead Sciences stock on 16 May 2005 worth over $95,600. On average, Paul trades about 1,972 units every 19 days since 2003. As of 30 April 2007 Paul still owns at least 12,750 units of Gilead Sciences stock.
You can see the complete history of Paul Berg stock trades at the bottom of the page.
Paul's mailing address filed with the SEC is BECKMAN CENTER, RM. B062, STANFORD UNIVERSITY SCHOOL OF MEDICINE, STANFORD, CA, 94305.
Over the last 22 years, insiders at Gilead Sciences have traded over $221,090,692 worth of Gilead Sciences stock and bought 30,121 units worth $1,879,767 . The most active insiders traders include John C Martin, Norbert W Bischofberger et John F Milligan. On average, Gilead Sciences executives and independent directors trade stock every 9 days with the average trade being worth of $3,341,365. The most recent stock trade was executed by Deborah H Telman on 10 September 2024, trading 639 units of GILD stock currently worth $51,721.
Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and COVID-19, including ledipasvir/sofosbuvir and sofosbuvir.
Gilead Sciences executives and other stock owners filed with the SEC include: